Advertisement

Sarcoma

  • Sezin Yuce Sari
  • Gozde Yazici
  • Melis Gultekin
  • Pervin Hurmuz
  • Murat Gurkaynak
  • Gokhan Ozyigit
Chapter

Abstract

This chapter on sarcomas is aiming to summarize the evidence-based current management for soft tissue sarcoma, retroperitoneal sarcoma, Ewing sarcoma, and rhabdomyosarcoma. We hope to ease the understanding in the appropriate delineation of tumor volumes/fields along with related case presentations covering diagnostic images, contouring, slice by slice final plan examples; accompanied by up-to-date key literature review.

References

  1. 1.
    Fletcher CDM, Unni K, Mertens F. World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.Google Scholar
  2. 2.
    Burningham Z, Hashibe M, Spector L, Schiffman JD. The epidemiology of sarcoma. Clin Sarcoma Res. 2012;2(1):14.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987;205(4):349–59.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Simon MA, Enneking WF. The management of soft-tissue sarcomas of the extremities. J Bone Joint Surg Am. 1976;58(3):317–27.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Enneking WF, Spanier SS, Malawer MM. The effect of the Anatomic setting on the results of surgical procedures for soft parts sarcoma of the thigh. Cancer. 1981;47(5):1005–22.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Daigeler A, Klein-Hitpass L, Stricker I, Muller O, Kuhnen C, Chromik AM, et al. Malignant fibrous histiocytoma—pleomorphic sarcoma, NOS gene expression, histology, and clinical course. A pilot study. Langenbeck’s Arch Surg. 2010;395(3):261–75.CrossRefGoogle Scholar
  7. 7.
    Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91(10):1914–26.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14(5):1679–89.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Parsons HM, Habermann EB, Tuttle TM, Al-Refaie WB. Conditional survival of extremity soft-tissue sarcoma: results beyond the staging system. Cancer. 2011;117(5):1055–60.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Gutierrez JC, Perez EA, Franceschi D, Moffat FL Jr, Livingstone AS, Koniaris LG. Outcomes for soft-tissue sarcoma in 8249 cases from a large state cancer registry. J Surg Res. 2007;141(1):105–14.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ, Robbins AS. Interaction of histologic subtype and histologic grade in predicting survival for soft-tissue sarcomas. J Am Coll Surg. 2010;210(2):191–8.e2.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Baldini EH, Goldberg J, Jenner C, Manola JB, Demetri GD, Fletcher CD, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999;17(10):3252–9.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Pisters PW, Pollock RE, Lewis VO, Yasko AW, Cormier JN, Respondek PM, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg. 2007;246(4):675–81; discussion 81-2.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Cahlon O, Spierer M, Brennan MF, Singer S, Alektiar KM. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer. 2008;112(12):2774–9.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Fabrizio PL, Stafford SL, Pritchard DJ. Extremity soft-tissue sarcomas selectively treated with surgery alone. Int J Radiat Oncol Biol Phys. 2000;48(1):227–32.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003;97(10):2544–53.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Lewis JJ, Leung D, Espat J, Woodruff JM, Brennan MF. Effect of reresection in extremity soft tissue sarcoma. Ann Surg. 2000;231(5):655–63.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14(3):859–68.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    O’Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235–41.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Alektiar KM, Leung D, Zelefsky MJ, Healey JH, Brennan MF. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol. 2002;9(1):48–56.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Nag S, Shasha D, Janjan N, Petersen I, Zaider M, American Brachytherapy Society. The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2001;49(4):1033–43.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Fein DA, Lee WR, Lanciano RM, Corn BW, Herbert SH, Hanlon AL, et al. Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy interval impact on local control? Int J Radiat Oncol Biol Phys. 1995;32(4):969–76.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Dickie CI, Griffin AM, Parent AL, Chung PW, Catton CN, Svensson J, et al. The relationship between local recurrence and radiotherapy treatment volume for soft tissue sarcomas treated with external beam radiotherapy and function preservation surgery. Int J Radiat Oncol Biol Phys. 2012;82(4):1528–34.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Kim B, Chen YL, Kirsch DG, Goldberg SI, Kobayashi W, Kung JH, et al. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys. 2010;77(3):843–50.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Mendenhall WM, Indelicato DJ, Scarborough MT, Zlotecki RA, Gibbs CP, Mendenhall NP, et al. The management of adult soft tissue sarcomas. Am J Clin Oncol. 2009;32(4):436–42.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, et al. Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface. Ann Surg Oncol. 2013;20(5):1494–9.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Cheng EY, Dusenbery KE, Winters MR, Thompson RC. Soft tissue sarcomas: preoperative versus postoperative radiotherapy. J Surg Oncol. 1996;61(2):90–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Davis AM, O'Sullivan B, Turcotte R, Bell R, Catton C, Chabot P, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75(1):48–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Holt GE, Griffin AM, Pintilie M, Wunder JS, Catton C, O’Sullivan B, et al. Fractures following radiotherapy and limb-salvage surgery for lower extremity soft-tissue sarcomas. A comparison of high-dose and low-dose radiotherapy. J Bone Joint Surg Am. 2005;87(2):315–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Al-Absi E, Farrokhyar F, Sharma R, Whelan K, Corbett T, Patel M, et al. A systematic review and meta-analysis of oncologic outcomes of pre- versus postoperative radiation in localized resectable soft-tissue sarcoma. Ann Surg Oncol. 2010;17(5):1367–74.PubMedCrossRefGoogle Scholar
  34. 34.
    Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol. 2008;26(20):3440–4.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Folkert MR, Singer S, Brennan MF, Kuk D, Qin LX, Kobayashi WK, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J Clin Oncol. 2014;32(29):3236–41.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Alektiar KM, Brennan MF, Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. Cancer. 2011;117(14):3229–34.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    O’Sullivan B, Griffin AM, Dickie CI, Sharpe MB, Chung PW, Catton CN, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013;119(10):1878–84.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Wang D, Zhang Q, Eisenberg BL, Kane JM, Li XA, Lucas D, et al. Significant reduction of late toxicities in patients with extremity sarcoma treated with image-guided radiation therapy to a reduced target volume: results of radiation therapy oncology group RTOG-0630 trial. J Clin Oncol. 2015;33(20):2231–8.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350(9092):1647–54.CrossRefGoogle Scholar
  40. 40.
    Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573–81.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, et al. A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma. Eur J Cancer. 2001;37(9):1096–103.PubMedCrossRefGoogle Scholar
  43. 43.
    Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010;116(19):4613–21.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56(4):1117–27.PubMedCrossRefGoogle Scholar
  45. 45.
    Wang D, Bosch W, Roberge D, Finkelstein SE, Petersen I, Haddock M, et al. RTOG sarcoma radiation oncologists reach consensus on gross tumor volume and clinical target volume on computed tomographic images for preoperative radiotherapy of primary soft tissue sarcoma of extremity in Radiation Therapy Oncology Group studies. Int J Radiat Oncol Biol Phys. 2011;81(4):e525–8.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    White LM, Wunder JS, Bell RS, O’Sullivan B, Catton C, Ferguson P, et al. Histologic assessment of peritumoral edema in soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2005;61(5):1439–45.PubMedCrossRefGoogle Scholar
  47. 47.
    Devisetty K, Kobayashi W, Suit HD, Goldberg SI, Niemierko A, Chen YL, et al. Low-dose neoadjuvant external beam radiation therapy for soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2011;80(3):779–86.PubMedCrossRefGoogle Scholar
  48. 48.
    Alektiar KM, Velasco J, Zelefsky MJ, Woodruff JM, Lewis JJ, Brennan MF. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2000;48(4):1051–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Holloway CL, Delaney TF, Alektiar KM, Devlin PM, O’Farrell DA, Demanes DJ. American Brachytherapy Society (ABS) consensus statement for sarcoma brachytherapy. Brachytherapy. 2013;12(3):179–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Porter GA, Baxter NN, Pisters PW. Retroperitoneal sarcoma: a population-based analysis of epidemiology, surgery, and radiotherapy. Cancer. 2006;106(7):1610–6.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Anaya DA, Lahat G, Wang X, Xiao L, Pisters PW, Cormier JN, et al. Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent. Ann Oncol. 2010;21(2):397–402.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Pacelli F, Tortorelli AP, Rosa F, Papa V, Bossola M, Sanchez AM, et al. Retroperitoneal soft tissue sarcoma: prognostic factors and therapeutic approaches. Tumori. 2008;94(4):497–504.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Schwarzbach MH, Hohenberger P. Current concepts in the management of retroperitoneal soft tissue sarcoma. Recent Results Cancer Res. 2009;179:301–19.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92(2):359–68.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–65.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Hassan I, Park SZ, Donohue JH, Nagorney DM, Kay PA, Nasciemento AG, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg. 2004;239(2):244–50.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Catton CN, O’Sullivan B, Kotwall C, Cummings B, Hao Y, Fornasier V. Outcome and prognosis in retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 1994;29(5):1005–10.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Gronchi A, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer. 2004;100(11):2448–55.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358–70; discussion 70-1.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Ferrario T, Karakousis CP. Retroperitoneal sarcomas: grade and survival. Arch Surg. 2003;138(3):248–51.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Baldini EH, Wang D, Haas RL, Catton CN, Indelicato DJ, Kirsch DG, et al. Treatment guidelines for preoperative radiation therapy for retroperitoneal sarcoma: preliminary consensus of an international expert panel. Int J Radiat Oncol Biol Phys. 2015;92(3):602–12.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Mori S, Hara R, Yanagi T, Sharp GC, Kumagai M, Asakura H, et al. Four-dimensional measurement of intrafractional respiratory motion of pancreatic tumors using a 256 multi-slice CT scanner. Radiother Oncol. 2009;92(2):231–7.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Wysocka B, Kassam Z, Lockwood G, Brierley J, Dawson LA, Buckley CA, et al. Interfraction and respiratory organ motion during conformal radiotherapy in gastric cancer. Int J Radiat Oncol Biol Phys. 2010;77(1):53–9.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Langen KM, Jones DT. Organ motion and its management. Int J Radiat Oncol Biol Phys. 2001;50(1):265–78.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Fein DA, Corn BW, Lanciano RM, Herbert SH, Hoffman JP, Coia LR. Management of retroperitoneal sarcomas: does dose escalation impact on locoregional control? Int J Radiat Oncol Biol Phys. 1995;31(1):129–34.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Sindelar WF, Kinsella TJ, Chen PW, DeLaney TF, Tepper JE, Rosenberg SA, et al. Intraoperative radiotherapy in retroperitoneal sarcomas. Final results of a prospective, randomized, clinical trial. Arch Surg. 1993;128(4):402–10.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Alektiar KM, Hu K, Anderson L, Brennan MF, Harrison LB. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47(1):157–63.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Jones JJ, Catton CN, O’Sullivan B, Couture J, Heisler RL, Kandel RA, et al. Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma. Ann Surg Oncol. 2002;9(4):346–54.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Gieschen HL, Spiro IJ, Suit HD, Ott MJ, Rattner DW, Ancukiewicz M, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50(1):127–31.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Petersen IA, Haddock MG, Donohue JH, Nagorney DM, Grill JP, Sargent DJ, et al. Use of intraoperative electron beam radiotherapy in the management of retroperitoneal soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2002;52(2):469–75.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Ahrens S, Hoffmann C, Jabar S, Braun-Munzinger G, Paulussen M, Dunst J, et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol. 1999;32(3):186–95.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Marcus RB Jr, Berrey BH, Graham-Pole J, Mendenhall NP, Scarborough MT. The treatment of Ewing’s sarcoma of bone at the University of Florida: 1969 to 1998. Clin Orthop Relat Res. 2002;397:290–7.CrossRefGoogle Scholar
  73. 73.
    Oberlin O, Patte C, Demeocq F, Lacombe MJ, Brunat-Mentigny M, Demaille MC, et al. The response to initial chemotherapy as a prognostic factor in localized Ewing’s sarcoma. Eur J Cancer Clin Oncol. 1985;21(4):463–7.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Bacci G, Ferrari S, Longhi A, Donati D, Barbieri E, Forni C, et al. Role of surgery in local treatment of Ewing's sarcoma of the extremities in patients undergoing adjuvant and neoadjuvant chemotherapy. Oncol Rep. 2004;11(1):111–20.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Schuck A, Ahrens S, Paulussen M, Kuhlen M, Konemann S, Rube C, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55(1):168–77.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Schuck A, Hofmann J, Rube C, Hillmann A, Ahrens S, Paulussen M, et al. Radiotherapy in Ewing’s sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92. Int J Radiat Oncol Biol Phys. 1998;42(5):1001–6.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol. 1990;8(10):1664–74.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Burgert EO Jr, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8(9):1514–24.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol. 2009;27(15):2536–41.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Womer RB, West DC, Krailo MD, Dickman PS, Pawel BR, Grier HE, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(33):4148–54.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Jurgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, et al. Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer. 1988;61(1):23–32.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol. 2001;19(6):1818–29.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, et al. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26(27):4385–93.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer. 1997;33(7):1061–9.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, et al. Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol. 1998;16(11):3628–33.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Rosen G, Caparros B, Mosende C, McCormick B, Huvos AG, Marcove RC. Curability of Ewing’s sarcoma and considerations for future therapeutic trials. Cancer. 1978;41(3):888–99.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol. 1995;13(11):2796–804.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, et al. Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol. 2003;21(18):3423–30.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Hayes FA, Thompson EI, Meyer WH, Kun L, Parham D, Rao B, et al. Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol. 1989;7(2):208–13.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, et al. Ifosfamide plus etoposide in newly diagnosed Ewing’s sarcoma of bone. J Clin Oncol. 1992;10(11):1737–42.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA, et al. Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol. 1999;17(1):180–90.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Bacci G, Mercuri M, Longhi A, Bertoni F, Barbieri E, Donati D, et al. Neoadjuvant chemotherapy for Ewing’s tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer. 2002;38(17):2243–51.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001;85(11):1646–54.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Gaspar N, Rey A, Berard PM, Michon J, Gentet JC, Tabone MD, et al. Risk adapted chemotherapy for localised Ewing’s sarcoma of bone: the French EW93 study. Eur J Cancer. 2012;48(9):1376–85.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Elomaa I, Blomqvist CP, Saeter G, Akerman M, Stenwig E, Wiebe T, et al. Five-year results in Ewing’s sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer. 2000;36(7):875–80.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284–91.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.Google Scholar
  99. 99.
    Dunst J, Jurgens H, Sauer R, Pape H, Paulussen M, Winkelmann W, et al. Radiation therapy in Ewing’s sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys. 1995;32(4):919–30.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Bacci G, Longhi A, Briccoli A, Bertoni F, Versari M, Picci P. The role of surgical margins in treatment of Ewing’s sarcoma family tumors: experience of a single institution with 512 patients treated with adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65(3):766–72.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Schuck A, Ahrens S, von Schorlemer I, Kuhlen M, Paulussen M, Hunold A, et al. Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2005;63(5):1562–7.PubMedCrossRefPubMedCentralGoogle Scholar
  102. 102.
    Ozaki T, Hillmann A, Hoffmann C, Rube C, Blasius S, Dunst J, et al. Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma. A report from the Cooperative Ewing’s Sarcoma Study. Cancer. 1996;78(4):892–900.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Donaldson S, Shuster J, Andreozzi C. The Pediatric Oncology Group (POG) experience in Ewing’s sarcoma of bone. Med Pediatr Oncol. 1989;17:283.Google Scholar
  104. 104.
    Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998;9(3):275–81.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Donaldson SS, Torrey M, Link MP, Glicksman A, Gilula L, Laurie F, et al. A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42(1):125–35.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Krasin MJ, Rodriguez-Galindo C, Billups CA, Davidoff AM, Neel MD, Merchant TE, et al. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys. 2004;60(3):830–8.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Fuchs B, Valenzuela RG, Inwards C, Sim FH, Rock MG. Complications in long-term survivors of Ewing sarcoma. Cancer. 2003;98(12):2687–92.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Bolek TW, Marcus RB Jr, Mendenhall NP, Scarborough MT, Graham-Pole J. Local control and functional results after twice-daily radiotherapy for Ewing’s sarcoma of the extremities. Int J Radiat Oncol Biol Phys. 1996;35(4):687–92.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Wagner LM, Neel MD, Pappo AS, Merchant TE, Poquette CA, Rao BN, et al. Fractures in pediatric Ewing sarcoma. J Pediatr Hematol Oncol. 2001;23(9):568–71.PubMedCrossRefPubMedCentralGoogle Scholar
  110. 110.
    Kuttesch JF Jr, Wexler LH, Marcus RB, Fairclough D, Weaver-McClure L, White M, et al. Second malignancies after Ewing’s sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996;14(10):2818–25.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317(10):588–93.PubMedCrossRefPubMedCentralGoogle Scholar
  112. 112.
    Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer. 1988;61(2):209–20.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Wolden SL, Anderson JR, Crist WM, Breneman JC, Wharam MD Jr, Wiener ES, et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J Clin Oncol. 1999;17(11):3468–75.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Maurer HM, Gehan EA, Beltangady M, Crist W, Dickman PS, Donaldson SS, et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer. 1993;71(5):1904–22.PubMedCrossRefPubMedCentralGoogle Scholar
  115. 115.
    Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13(3):610–30.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19(12):3091–102.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma—a report from the IRSG. Int J Radiat Oncol Biol Phys. 2001;51(3):718–28.PubMedCrossRefPubMedCentralGoogle Scholar
  118. 118.
    Wiener ES, Anderson JR, Ojimba JI, Lobe TE, Paidas C, Andrassy RJ, et al. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg. 2001;10(3):146–52.PubMedCrossRefPubMedCentralGoogle Scholar
  119. 119.
    Raney RB, Walterhouse DO, Meza JL, Andrassy RJ, Breneman JC, Crist WM, et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. J Clin Oncol. 2011;29(10):1312–8.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Breneman J, Meza J, Donaldson SS, Raney RB, Wolden S, Michalski J, et al. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children’s Oncology Group D9602 study. Int J Radiat Oncol Biol Phys. 2012;83(2):720–6.PubMedCrossRefPubMedCentralGoogle Scholar
  121. 121.
    Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children’s Oncology Group study D9803. J Clin Oncol. 2009;27(31):5182–8.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Walterhouse DO, Meza JL, Breneman JC, Donaldson SS, Hayes-Jordan A, Pappo AS, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children’s Oncology Group. Pediatr Blood Cancer. 2011;57(1):76–83.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Rodary C, Rey A, Olive D, Flamant F, Quintana E, Brunat-Mentigny M, et al. Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis. Med Pediatr Oncol. 1988;16(2):71–7.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84. Eur J Cancer. 1998;34(7):1050–62.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology—SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol. 2005;23(12):2618–28.PubMedCrossRefPubMedCentralGoogle Scholar
  126. 126.
    Donaldson SS, Anderson JR. Rhabdomyosarcoma: many similarities, a few philosophical differences. J Clin Oncol. 2005;23(12):2586–7.PubMedCrossRefPubMedCentralGoogle Scholar
  127. 127.
    Koscielniak E, Jurgens H, Winkler K, Burger D, Herbst M, Keim M, et al. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study. Cancer. 1992;70(10):2557–67.PubMedCrossRefPubMedCentralGoogle Scholar
  128. 128.
    Koscielniak E, Harms D, Henze G, Jurgens H, Gadner H, Herbst M, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17(12):3706–19.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27(9):1446–55.PubMedCrossRefPubMedCentralGoogle Scholar
  130. 130.
    Michalski JM, Meza J, Breneman JC, Wolden SL, Laurie F, Jodoin M, et al. Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. Int J Radiat Oncol Biol Phys. 2004;59(4):1027–38.PubMedCrossRefPubMedCentralGoogle Scholar
  131. 131.
    Rousseau P, Flamant F, Quintana E, Voute PA, Gentet JC. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study. J Clin Oncol. 1994;12(3):516–21.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Rodary C, Gehan EA, Flamant F, Treuner J, Carli M, Auquier A, et al. Prognostic factors in 951 nonmetastatic rhabdomyosarcoma in children: a report from the International Rhabdomyosarcoma Workshop. Med Pediatr Oncol. 1991;19(2):89–95.PubMedCrossRefPubMedCentralGoogle Scholar
  133. 133.
    Raney RB Jr, Gehan EA, Hays DM, Tefft M, Newton WA Jr, Haeberlen V, et al. Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcoma of the bladder, prostate, vagina, uterus, and cervix. A comparison of the results in Intergroup Rhabdomyosarcoma Studies I and II. Cancer. 1990;66(10):2072–81.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sezin Yuce Sari
    • 1
  • Gozde Yazici
    • 1
  • Melis Gultekin
    • 1
  • Pervin Hurmuz
    • 1
  • Murat Gurkaynak
    • 1
  • Gokhan Ozyigit
    • 1
  1. 1.Department of Radiation Oncology, Faculty of MedicineHacettepe UniversityAnkaraTurkey

Personalised recommendations